What is it? Evusheld is a monoclonal antibody, but different than the other medications listed above. It combines two drugs, tixagevimab and cilgavimab.
It is not designed to treat COVID-19; rather, its purpose is to keep immunocompromised people who do not respond to vaccination from getting sick.
Developed by AstraZeneca, it is the first long-acting antibody to receive an EUA for pre-exposure prevention of COVID-19.
When it was authorized: December 2021.
Who can take it: Anyone 12 years or older who weighs at least 88 pounds and is at risk for severe illness—or those who cannot receive COVID-19 vaccines.